Literature DB >> 17314037

The EGF receptor family: spearheading a merger of signaling and therapeutics.

Erez M Bublil1, Yosef Yarden.   

Abstract

The ErbB receptor tyrosine kinases evolved as key regulatory entities enabling the extracellular milieu to communicate with the intracellular machinery to bring forth the appropriate biological response in an ever-changing environment. Since its discovery, many aspects of the ErbB family have been deciphered, with emphasis on aberration of signaling in human diseases. However, only now, with the availability of the atomic coordinates of these receptors, can we construct a comprehensive model of the mechanisms underlying ligand-induced receptor dimerization and subsequent tyrosine kinase activation. Furthermore, the recent introduction of new high-throughput screening methodologies, combined with the materialization of a systems biology perspective, reveals an overwhelming network complexity, enabling robust signaling and evolvability. This knowledge is likely to impact our view of diseases as system perturbations and resistance to ErbB-targeted therapeutics as manifestations of robustness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314037     DOI: 10.1016/j.ceb.2007.02.008

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  159 in total

Review 1.  Mathematical simulation of membrane protein clustering for efficient signal transduction.

Authors:  Krishnan Radhakrishnan; Ádám Halász; Meghan M McCabe; Jeremy S Edwards; Bridget S Wilson
Journal:  Ann Biomed Eng       Date:  2012-06-06       Impact factor: 3.934

2.  miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.

Authors:  Hongwei Liang; Minghui Liu; Xin Yan; Yong Zhou; Wengong Wang; Xueliang Wang; Zheng Fu; Nan Wang; Suyang Zhang; Yanbo Wang; Ke Zen; Chen-Yu Zhang; Dongxia Hou; Jing Li; Xi Chen
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

3.  Association between EGF +61A/G polymorphism and gastric cancer in Caucasians.

Authors:  Ana Paula Araújo; Bruno M Costa; Ana L Pinto-Correia; Maria Fragoso; Paula Ferreira; Mário Dinis-Ribeiro; Sandra Costa; Rui M Reis; Rui Medeiros
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 4.  The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation.

Authors:  Brian Wadugu; Bernhard Kühn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

5.  Growth factor- and cytokine-driven pathways governing liver stemness and differentiation.

Authors:  Aránzazu Sánchez; Isabel Fabregat
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 6.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

7.  Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK.

Authors:  Yuji Kamioka; Shuhei Yasuda; Yoshihisa Fujita; Kazuhiro Aoki; Michiyuki Matsuda
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

8.  Neuregulin-4 is a survival factor for colon epithelial cells both in culture and in vivo.

Authors:  Jessica K Bernard; Sean P McCann; Vrinda Bhardwaj; Mary K Washington; Mark R Frey
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

10.  ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

Authors:  Christopher S Williams; Jessica K Bernard; Michelle Demory Beckler; Dana Almohazey; Mary Kay Washington; Jesse J Smith; Mark R Frey
Journal:  Carcinogenesis       Date:  2015-04-27       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.